HMBD-002 Posters Posters - 2022 Publications & Posters SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response Continue Reading
HMBD-002 Posters Posters - 2022 Publications & Posters SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
